Core Viewpoint - North Sea Kangcheng-B (01228.HK) has entered into a subscription agreement with WuXi Biologics HealthCare Venture, agreeing to issue and the subscriber agreeing to purchase a total of 84.036 million subscription shares at a price of HKD 2.38 per share, representing approximately 16.44% of the existing issued shares as of the announcement date [1] Group 1 - The total amount raised from the subscription is expected to be approximately HKD 200 million, with the estimated net proceeds from the subscription being around HKD 199 million [1] - The company plans to use the net proceeds for (i) working capital and regulatory maintenance for commercialized products; (ii) research and development expenses for existing product lines; and (iii) settling trade payables of the group [1]
北海康成-B(01228.HK)拟发行8403.36万股认购股份 总筹2亿港元